Track the 화일약품 stock price and the full management transaction log of the company, a listed equity based in South Korea. Shares are listed on KR KR, under the oversight of DART (FSS). Operating in the Health Care sector, 화일약품 has published 65 public disclosures. Market capitalisation: €74.9bn. The latest transaction was filed on 2 July 2026 (Purchase). Among the most active insiders: CG인바이츠. The full history is openly available.
64
Insider Decl.
n/a
Thresholds
€2,733
25 ops.
Buy Volume
€1m
17 ops.
Sell Volume
24Σ signal
Buys €2,733€1m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 19,937 of 28,065 companies
37.7
score / 100
Value
38
Quality
38
FCF yld11%
Earn yld-0.3%
EV/EBITDA57.1x
ROE1.9%
Gross mgn6.6%
Net mgn-0.2%
Debt/EBITDA0.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
화일약품 is a healthcare and pharmaceutical company listed on the XKRX market. It specializes in the manufacturing of pharmaceutical products and healthcare solutions.